BioCentury | Jan 10, 2020
Product Development

Seeking structural endpoints for OA

As the first disease-modifying therapies for osteoarthritis enter late-stage development, companies are testing new endpoints that can capture effects on joint structure instead of relying on traditional pain-related readouts. Most are converging on MRI imaging...
BC Innovations | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
BC Week In Review | Sep 29, 2017
Clinical News

Medivir reports Phase IIa data of MIV-711 for OA

Medivir AB (SSE:MVIR B) reported top-line data showing that MIV-711 slowed the degenerative effects of moderate osteoarthritis (OA) on both bone and cartilage of the knee in the Phase IIa MIV-711-201 trial. The company said...
BC Extra | Sep 26, 2017
Clinical News

Medivir rises on Phase IIa OA data

Medivir AB (SSE:MVIR B) gained SEK14.75 (25%) to SEK74.75 on Tuesday after reporting that MIV-711 slowed the degenerative effects of moderate osteoarthritis on both bone and cartilage of the knee in the Phase IIa MIV-711-201...
BC Week In Review | Jun 22, 2017
Clinical News

Medivir continues extension study of MIV-711 in knee OA

An IDMC recommended continuation of a Phase IIa extension study of MIV-711 from Medivir AB (SSE:MVIR B) in 50 patients with moderate knee osteoarthritis (OA). The open-label, international extension is evaluating the safety of once-daily...
BC Week In Review | Dec 9, 2016
Clinical News

MIV-711: Ph IIa MIV-711-201 ongoing

An IDMC recommended continuation for the third time the double-blind, placebo-controlled, European Phase IIa MIV-711-201 trial of oral MIV-711 based on safety data from the first 150 patients with knee joint OA who completed 3...
BC Week In Review | Nov 2, 2016
Clinical News

MIV-711: Ph IIa completed enrollment

Medivir completed enrollment of 244 patients with knee joint OA in the double-blind, placebo-controlled, European Phase IIa MIV-711-201 trial evaluating 100 and 200 mg oral MIV-711 once daily for 6 months. Medivir AB (SSE:MVIR B),...
BC Week In Review | Oct 17, 2016
Company News

Medivir cancer news

Medivir AB Medivir will reduce headcount by 30 (25%) to about 90 and focus its pipeline exclusively on cancer. Cuts will come from the early research organization and administrative and commercial support functions. Medivir said...
BC Week In Review | Oct 10, 2016
Clinical News

MIV-711: Phase IIa ongoing

An IDMC recommended continuation of the double-blind, placebo-controlled, European Phase IIa MIV-711-201 trial of oral MIV-711 based on safety data from 50 patients with knee joint OA who completed 3 months of treatment. The trial...
BC Week In Review | Sep 5, 2016
Company News

Medivir deal

Medivir will split into two independent companies, one focused on R&D and one housing the company’s commercial products. The company expects to complete the division by year end. Medivir’s marketed products include HCV treatment Olysio...
Items per page:
1 - 10 of 22